3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
6
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neuroblastoma
6
Glioblastoma
6
Melanoma
5
Neoplasms
3
Leukemia, Myeloid, Acute
3
Glioma
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Pathologic Complete Response
2
Ovarian Neoplasms
2
Osteosarcoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Gliosarcoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Wilms Tumor
1
Vaccinia
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Interventions
pembrolizumab
98
Gemcitabine
70
Paclitaxel
59
Docetaxel
52
Carboplatin
49
Cisplatin
40
Nivolumab
39
Capecitabine
35
Pemetrexed
33
Fluorouracil
32
Bevacizumab
32
Cetuximab
31
130-nm albumin-bound paclitaxel
28
Trastuzumab
26
Irinotecan
24
Albumin-Bound Paclitaxel
24
Fulvestrant
22
Leucovorin
20
Oxaliplatin
18
Panitumumab
17
abemaciclib
16
Ipilimumab
16
Cyclophosphamide
15
cemiplimab
14
atezolizumab
14
Letrozole
14
palbociclib
12
Lapatinib
12
Drug Therapy
12
Doxorubicin
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasm Metastasis
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT01322490
2019-09-04
Prospect
Bavarian Nordic
Phase 3
Completed
1,297 enrolled
16 charts